{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:59:23Z","timestamp":1791845963560,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010012","name":"National Aerospace Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.cytogfr.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:15:28Z","timestamp":1588824928000},"page":"66-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":344,"special_numbering":"C","title":["COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons"],"prefix":"10.1016","volume":"53","author":[{"given":"Shivraj Hariram","family":"Nile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Nile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyin","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2020.05.002_bib0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0015","doi-asserted-by":"crossref","first-page":"105951","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives","author":"Li","year":"2020","journal-title":"Int. J. Antimicrobial Agents"},{"issue":"10223","key":"10.1016\/j.cytogfr.2020.05.002_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","author":"Li","year":"2020","journal-title":"J. Pharm. Analysis"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0055","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications","volume":"15","author":"Wang","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0060","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41418-017-0006-2","article-title":"Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101300","article-title":"Global virus outbreaks: interferons as 1st responders","volume":"43","author":"Wang","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.aivir.2016.08.006","article-title":"Interaction of SARS and MERS Coronaviruses with the antiviral interferon response","volume":"96","author":"Kindler","year":"2016","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.cytogfr.2020.05.002_bib0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0095","author":"Uppangala"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic ef\ufb01cacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0105","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00134-020-05967-x","article-title":"Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists","volume":"46","author":"Bouadma","year":"2020","journal-title":"Intensive Care Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.05.002_bib0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3201\/eid1002.030482","article-title":"Interferon-beta 1a and SARS coronavirus replication","volume":"10","author":"Hensley","year":"2004","journal-title":"Emerg. Infect. Dis."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.05.002_bib0120","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-\u03b12b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.drudis.2019.01.018","article-title":"Repurposing host-based therapeutics to control coronavirus and influenza virus","volume":"24","author":"Li","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses -drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0140","unstructured":"https:\/\/www.cusabio.com\/COVID-19-Cytokine-Storm. Accessed on 01\/05\/2020."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm\u2019 in COVID-19","author":"Ye","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0150","article-title":"Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 Pneumonia","author":"Chen","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0155","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0160","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19","author":"Muralidharan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2020.03.026","article-title":"Angiotensin-converting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19)","author":"Sanchis-Gomar","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0175","doi-asserted-by":"crossref","DOI":"10.2174\/0929867327666200416131117","article-title":"SARS-CoV-2: Recent Reports on Antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus","volume":"27","author":"Costanzo","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0185","series-title":"Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19","author":"Okasha","year":"2020"},{"key":"10.1016\/j.cytogfr.2020.05.002_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610120300708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610120300708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:57:12Z","timestamp":1761217032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610120300708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"alternative-id":["S1359610120300708"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2020.05.002","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}